Hyloris Pharmaceuticals SA (HYL.BR) | Investment Case

1. Company Snapshot

1.a. Company Description

Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas.The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease.It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection.

Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.

Show Full description

1.b. Last Insights on HYL

Hyloris Pharmaceuticals SA's recent momentum is driven by its strategic partnership with RedHill Biopharma for the development of Bekinda, a treatment for acute gastroenteritis. The agreement brings an upfront payment and potential milestone payments of up to $60 million, bolstering Hyloris' financial position. This deal highlights the company's ability to leverage its pipeline and generate value through collaborations. With a strengthened balance sheet, Hyloris is well-positioned to advance its development programs.

1.c. Company Highlights

Last Price	6
Change Percentage	-1.32%
Open	6.08
Previous Close	6.08
Market Cap ( Millions)	168
Volume	3268
Year High	7.26
Year Low	4.42
M A 50	5.82
M A 200	6.07

FCF Yield	-3.00%
Dividend Yield	0.00%
ROE	-13.95%
Debt / Equity	5.65%
Net Debt / EBIDTA	717.95%
Price To Book	5.42
Price Earnings Ratio	-37.88
Price To FCF	-33.3
Price To sales	21.76
EV / EBITDA	-48.2

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

RedHill and Hyloris sign agreement for Bekinda’s development

Feb -26

Source:

Hyloris Reports Full Year Results for 2023 & Provides Business Outlook

Mar -14

Source:

Communication at the request of the FSMA on the transactions with Qliniq

Mar -14

Source:

Hyloris to Report 2023 Full-Year Results on 14 March 2024

Mar -08

Source:

Hyloris Announces Launch of Maxigesic® IV in the U.S. and approval In Canada

Feb -27

Source:

Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures

Feb -14

Source:

Hyloris and Purna Female Healthcare Announce Positive Results from Phase 2 Trial in Patients with Acute Vulvovaginal Candidiasis (VVC)

Jan -30

Source:

Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS)

Jan -18

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Pharmaceuticals

Expected Growth: 9.27%

Hyloris Pharmaceuticals SA's 9.27% growth is driven by increasing demand for specialty medicines, strategic partnerships, and expansion into emerging markets. Additionally, the company's focus on rare disease treatments and innovative pipeline products contribute to its growth momentum.

7. Detailed Products

Rybelsus

Rybelsus is an oral glucagon-like peptide-1 (GLP-1) receptor agonist, used to treat type 2 diabetes.

Xerava

Xerava is a tetracycline-class antibacterial, used to treat community-acquired bacterial pneumonia (CABP).

Suliqua

Suliqua is a fixed-dose combination of insulin glargine and lixisenatide, used to treat type 2 diabetes.

Adlyxin

Adlyxin is a glucagon-like peptide-1 (GLP-1) receptor agonist, used to treat type 2 diabetes.

8. Hyloris Pharmaceuticals SA's Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Hyloris Pharmaceuticals SA is moderate due to the presence of alternative pharmaceutical companies offering similar products.

Bargaining Power Of Customers

The bargaining power of customers for Hyloris Pharmaceuticals SA is low due to the company's strong brand reputation and limited availability of alternative products.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Hyloris Pharmaceuticals SA is moderate due to the presence of multiple suppliers and the company's moderate dependence on them.

Threat Of New Entrants

The threat of new entrants for Hyloris Pharmaceuticals SA is high due to the attractiveness of the pharmaceutical industry and the ease of entry for new companies.

Intensity Of Rivalry

The intensity of rivalry for Hyloris Pharmaceuticals SA is high due to the presence of multiple competitors and the high stakes in the pharmaceutical industry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	12.00%
Debt Cost	6.77%
Equity Weight	88.00%
Equity Cost	6.77%
WACC	6.77%
Leverage	13.64%

11. Quality Control: Hyloris Pharmaceuticals SA passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Basilea Pharmaceutica

A-Score: 5.4/10

Value: 5.4

Growth: 8.1

Quality: 8.2

Yield: 0.0

Momentum: 5.5

Volatility: 5.3

1-Year Total Return ->

Gubra

A-Score: 4.5/10

Value: 6.8

Growth: 2.4

Quality: 9.9

Yield: 5.0

Momentum: 2.5

Volatility: 0.3

1-Year Total Return ->

Hyloris Pharma

A-Score: 3.8/10

Value: 6.2

Growth: 6.2

Quality: 3.9

Yield: 0.0

Momentum: 5.0

Volatility: 1.3

1-Year Total Return ->

Compugen

A-Score: 3.8/10

Value: 6.8

Growth: 7.4

Quality: 4.4

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

BioArctic

A-Score: 3.2/10

Value: 1.5

Growth: 2.6

Quality: 9.9

Yield: 0.0

Momentum: 5.0

Volatility: 0.3

1-Year Total Return ->

MediWound

A-Score: 2.9/10

Value: 6.0

Growth: 3.3

Quality: 3.3

Yield: 0.0

Momentum: 3.5

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

26.98%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

6.77%

Hyloris Pharmaceuticals SA - BE0974363955

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on HYL

1.c. Company Highlights

Average Yield

Average Growth

Average Quality

Medium Volatility

Fairly Valued

More Volatile

Weak Momentum

Strong Momentum

Stable Momentum

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Pharmaceuticals

Expected Growth: 9.27%

7. Detailed Products

Rybelsus

Xerava

Suliqua

Adlyxin

8. Hyloris Pharmaceuticals SA's Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Hyloris Pharmaceuticals SA passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

6.0$

Current Price

6$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA